Thursday, April 25, 2024, Washington, DC, 6:00 PM – 8:00 PM Eastern Time

What I Tell My Patients: Integrating New Research Information into Current Clinical Care

A Complimentary NCPD Hybrid Symposium Series Held During the 49th Annual ONS Congress

Chronic Lymphocytic Leukemia and Bispecific Antibodies in the Management of Lymphoma

 
Location
Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Program Schedule — Eastern Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — NCPD Dinner Meeting

Meeting Room
Independence Ballroom (Meeting Level 4)

This event will also be webcast live.
Please see Registration tab for details.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.  
 
Faculty
John N Allan, MD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
New York, New York

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Robin Klebig, MSN, APRN, CNP, AOCNP
Hematology Outpatient APP Supervisor
Assistant Professor of Medicine
Nurse Practitioner, Lymphoma Group
Division of Hematology
Mayo Clinic
Rochester, Minnesota


Mollie Moran, APRN-CNP, AOCNP
Nurse Practitioner
The James Cancer Hospital and Solove Research Institute
The Ohio State University
Columbus, Ohio

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Meeting space has been assigned to provide a satellite symposium supported by AbbVie Inc, Genentech, a member of the Roche Group, and Genmab US Inc and AbbVie Inc during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24-28, 2024 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Eastern Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — NCPD Dinner Meeting

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

What I Tell My Patients About ...

First-Line Therapy for CLL

  • Implications of various biomarkers, such as IGHV mutation, deletion 17p and TP53 mutation, for prognosis and therapeutic selection
  • Indications for initiating active therapy for patients with previously untreated CLL
  • Outcomes observed with venetoclax-based up-front treatment for patients with CLL
  • Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve CLL

The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL

  • Relevant comorbidities, such as hypertension, preexisting cardiac arrhythmias and chronic kidney disease, that can influence clinical decision-making for patients with CLL
  • Documented effect of the concomitant use of anticoagulation therapy on the risk of cardiac adverse events with Bruton tyrosine kinase (BTK) inhibitors
  • Potential interactions between BTK inhibitors or venetoclax and other prescription drugs or over-the-counter medications and supplements

Toxicities and Other Practical Considerations with Venetoclax-Based Treatment

  • Key factors placing patients at risk for tumor lysis syndrome (TLS) with venetoclax; approaches to monitoring for and management of laboratory and clinical TLS
  • Spectrum, incidence, severity and management of other toxicities reported with venetoclax, such as neutropenia, infections and gastrointestinal disorders
  • Definition and clinical significance of minimal residual disease (MRD)
  • Current role, if any, of MRD assessment in the management of CLL; implications for the duration of venetoclax-based treatment

The Tolerability of Available BTK Inhibitors

  • Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved BTK inhibitors
  • Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding
  • Spectrum and frequency of clinically relevant non-cardiovascular toxicities, including cytopenias, infections,headache, dermatologic symptoms, arthralgias or myalgia and gastrointestinal-related events
  • Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving BTK inhibitors

The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax

  • Mechanistic rationale for combining BTK inhibitors and venetoclax with and without CD20 antibodies for CLL
  • Published data sets evaluating ibrutinib/venetoclax for newly diagnosed and relapsed/refractory
    (R/R) CLL
  • Available data with acalabrutinib or zanubrutinib in combination with venetoclax with or without an anti-CD20 antibody
  • Ongoing Phase III studies assessing novel doublet and triplet combinations for previously untreated and R/R disease; potential clinical role of this strategy
  • Incidence and severity of clinically relevant toxicities encountered when combining BTK inhibitors and venetoclax

The Selection and Sequencing of Therapies for R/R CLL

  • Long-term follow-up from Phase III trials evaluating BTK inhibitors and venetoclax for R/R CLL
  • Role of rechallenging with agents used in a prior line of treatment
  • Antitumor activity documented with pirtobrutinib in patients with R/R CLL; current clinical role
  • Biological rationale for and available data with CD19-directed chimeric antigen receptor (CAR) T-cell therapy for CLL; recent FDA approval

BISPECIFIC ANTIBODIES IN THE MANAGEMENT OF LYMPHOMA

What I Tell My Patients About ...

Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (NHL)

  • Potential therapeutic advantages over traditional monoclonal antibodies of using bispecific antibodies to engage 2 disease targets with 1 molecule
  • Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL
  • Mechanistic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies, such as epcoritamab, glofitamab, mosunetuzumab and odronextamab
  • Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies relative to CAR T-cell therapy

Bispecific Antibodies in the Management of Follicular Lymphoma (FL)

  • Frequency, depth and durability of responses to mosunetuzumab in patients with R/R FL
  • Recent FDA approval of mosunetuzumab for patients with FL after 2 or more lines of systemic therapy
  • Optimal integration of mosunetuzumab into FL treatment algorithms
  • Available data and ongoing research with other CD20 x CD3 bispecific antibodies for FL, such as epcoritamab, glofitamab and odronextamab

The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

  • Pivotal clinical trial results with glofitamab and with epcoritamab for multiregimen-relapsed DLBCL
  • FDA-approved indications for glofitamab and epcoritamab in patients with DLBCL
  • Optimal sequencing of bispecific antibodies relative to other available therapies for DLBCL; patient and disease-related factors

Cytokine Release Syndrome (CRS) and Neurotoxicity with Bispecific Antibodies

  • Incidence and severity of CRS and neurotoxicity with bispecific antibody therapy in patients with NHL
  • Time course for and common signs and symptoms of CRS and neurotoxicity
  • Optimal monitoring of patients for early detection of CRS and neurotoxicity
  • Guideline-endorsed approaches to the mitigation and management of CRS and neurotoxicity

Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy

  • Incidence of cytopenias, infections and tumor flare with bispecific antibody therapy in pivotal clinical trials
  • Spectrum, frequency and severity of other common adverse events with bispecific antibodies among patients with NHL, such as fatigue, rash, musculoskeletal pain and laboratory anomalies
  • Counseling patients about the importance of monitoring for and reporting symptoms of common and less common adverse events with bispecific antibodies
  • Strategies to manage side effects of bispecific antibodies in routine practice; appropriate thresholds for dose modification and treatment discontinuation

Other Practical Considerations with the Use of Bispecific Antibodies

  • Routes of administration and step-up dosing schedules of various bispecific antibodies
  • Recommended premedication and prophylaxis for patients with NHL about to begin treatment with bispecific antibodies
  • Educating patients about the need for hospitalization with specific bispecific antibody therapies; timing and duration of hospitalization
  • Anticipated duration of treatment with bispecific antibody therapy

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Appreciate the scientific rationale for the investigation of combined Bruton tyrosine kinase and Bcl-2 inhibition, and review safety and efficacy data with this strategy for newly diagnosed CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic therapies commonly employed in the management of CLL.
  • Appraise the scientific rationale for the evaluation of CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma, and understand the similarities and differences among currently available and investigational agents in this class.
  • Evaluate available research findings with CD20 x CD3 bispecific antibodies for R/R follicular lymphoma and diffuse large B-cell lymphoma, and reflect on the current role of these treatments in patient care.
  • Recognize adverse events associated with CD20 x CD3 bispecific antibodies, and implement strategies to educate patients and manage complications.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification
This program will be submitted for ONCC/ILNA certification.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Klebig and Ms Moran— No relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr AllanAdvisory Committee: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Merck; Speakers Bureaus: AbbVie Inc, BeiGene Ltd, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company. Dr KahlConsulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Novartis, Roche Laboratories Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Genentech, a member of the Roche Group, and Genmab US Inc and AbbVie Inc.

Marriott Marquis Washington, DC
901 Massachusetts Avenue NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence Ballroom (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2024 ONS Congress and is connected to the Walter E Washington Convention Center by an underground concourse.

 

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

There is no registration fee for this event. For the in-person symposium in Washington, DC, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ONS Congress.

IN-PERSON Registration for nurses and other healthcare providers

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.